Clinical Trial Update: Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing lung deposition of the budesonide/formoterol (BDP/formoterol) combination delivered by a NEXT inhaler in healthy, asthmatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BDP/Formoterol (budesonide/formoterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Pulmonary Disease, Chronic Obstructive, Asthma | Phase 1, Phase 2 | Status: COMPLETED